Braveheart Bio prices IPO at $18 per share, raising $382.5 million

Braveheart Bio, Inc. priced its initial public offering at $18.00 per share¹, offering 21,250,000 shares of common stock¹. The stock has been approved for listing on The Nasdaq Global Market under the symbol "BRVE."¹ The offering totals $382,500,000 in gross proceeds, with net proceeds of $16.74 per share to the company after underwriting discounts.¹

Underwriters have an option to purchase up to an additional 3,187,500 shares¹ at the IPO price. Fidelity Management & Research Company LLC gave a non-binding indication of interest to purchase up to $75 million in shares¹ as a cornerstone investor. Shares are expected to be delivered on or about August 7, 2026.¹

The company is a clinical-stage biopharmaceutical company focused on hypertrophic cardiomyopathy, with lead candidate BHB-1893, an oral small-molecule cardiac myosin inhibitor being developed for obstructive and non-obstructive HCM¹. BHB-1893 was originally discovered and developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. in China, and all completed trials to date were designed, sponsored, and conducted by Hengrui¹.

Braveheart plans to advance the drug through global late-stage trials, with LIONHEART-HCM, its global Phase 3 trial in oHCM, expected to begin in the second half of 2026, and NOBLEHEART-HCM, its global Phase 3 trial in nHCM, expected to begin in the first half of 2027¹.

Financially, the company reported net losses of $14.3 million for the three months ended March 31, 2026, and $66.1 million for the year ended December 31, 2025, with an accumulated deficit of $80.3 million as of March 31, 2026¹.